Successful major surgical recovery of a patient following haploidentical stem cell transplantation for chronic myeloid leukemia in blast crisis and aspergillosis.
A 44-year-old woman who underwent haploidentical stem cell transplantation (haplo SCT) for chronic myeloid leukemia in blast crisis and aspergillosis was admitted to the emergency room 7 months later because of severe right upper quadrant abdominal pain, fever, leukocytosis and peritoneal signs. Computer tomography disclosed cholecystitis and gallbladder perforation. Within hours, she underwent urgent open laparatomy and cholecystectomy. The postoperative period was uneventful and she was discharged 10 days later without any complications. Currently, she is 2(1/2) years posttransplantation in full hematological, cytogenetic and molecular remission with 100% Karnofsky performance status. Most notably, normal and fast recovery was observed following major surgery 7 months post-haplo SCT which is usually considered to result in long-lasting immunosuppression and malfunction of the immune system.
Varadi
Gabor
G
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Svirsky
On
O
Nagler
Arnon
A
D000328:Adult; D000074323:Alemtuzumab; D000666:Amphotericin B / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications* / Q000188:drug therapy; D001752:Blast Crisis / Q000150:complications / Q000628:therapy*; D017081:Cholecystectomy, Laparoscopic; D002764:Cholecystitis / Q000150:complications / Q000382:microbiology / Q000601:surgery; D005260:Female; D005705:Gallbladder Diseases / Q000209:etiology / Q000382:microbiology / Q000601:surgery; D006086:Graft vs Host Disease / Q000517:prevention & control; D020544:Graft vs Leukemia Effect; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation; D006648:Histocompatibility; D006801:Humans; D016867:Immunocompromised Host; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy*; D008172:Lung Diseases, Fungal / Q000150:complications* / Q000188:drug therapy; D008212:Lymphocyte Depletion; D012422:Rupture, Spontaneous; D013203:Staphylococcal Infections / Q000150:complications / Q000601:surgery; D013601:T-Lymphocytes / Q000276:immunology; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000935:Antifungal Agents; D000074323:Alemtuzumab; D000666:Amphotericin B